Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

• Main Authors: Thomas Rodier (Author), Alicja Puszkiel (Author), Evelina Cardoso (Author), David Balakirouchenane (Author), Céline Narjoz (Author), Jennifer Arrondeau (Author), Vincent Fallet (Author), Nihel Khoudour (Author), Monia Guidi (Author), Michel Vidal (Author), Xavier Declèves (Author), Chantal Csajka (Author), Jérôme Alexandre (Author), Jacques Cadranel (Author), Elizabeth Fabre (Author), Marie Wislez (Author), François Goldwasser (Author), Benoit Blanchet (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in plasma exposure. The aim of this study was to evaluate the exposure-response relationship for...